The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?

OncoImmunology

Volumn 6, Issue 4, 2017, Pages

  Böger, Christine ^a   Behrens, Hans Michael ^a   Krüger, Sandra ^a   Röcken, Christoph ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Dies1; EBV; immunotherapy; MSI; V domain Ig suppressor of T cell activation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROGRAMMED DEATH 1 LIGAND 1; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; CELL CYCLE CHECKPOINT; CONTROLLED STUDY; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENOTYPE; GNAS GENE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; KRAS GENE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PIK3CA GENE; STOMACH CARCINOMA; TUMOR GROWTH; TUMOR LOCALIZATION; V SET DOMAIN CONTAINING T CELL ACTIVATION;

EID: 85017182561     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1293215     Document Type: Article

References (24)

1. Goode EF, Smyth EC. Immunotherapy for gastroesophageal cancer. J Clin Med 2016; 5(10):pii:E84; PMID:27669318; http://dx.doi.org/10.3390/jcm5100084
2. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513(7517):202-9; PMID:25079317; http://dx.doi.org/10.1038/nature13480
3. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014; 46(6):573-82; PMID:24816253; http://dx.doi.org/10.1038/ng.2983
4. Böger C, Behrens HM, Mathiak M, Krüger S, Kalthoff H, Röcken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016; 7(17):24269-83; PMID:27009855; http://dx.doi.org/10.18632/oncotarget.8169
5. Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res 2016; 4(11):959-67; PMID:27671167; http://dx.doi.org/10.1158/2326-6066.CIR-16-0143
6. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, et al. Immune evasion in cancer:mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015; 35 Suppl:S185-98; PMID:25818339; http://dx.doi.org/10.1016/j.semcancer.2015.03.004
7. Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, Lu LF, Gondek D, Wang Y, Fava RA, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 2011; 208(3):577-92; PMID:21383057; http://dx.doi.org/10.1084/jem.20100619
8. Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, Noelle RJ, Wang L. VISTA regulates the development of protective antitumor immunity. Cancer Res 2014; 74(7):1933-44; PMID:24691994; http://dx.doi.org/10.1158/0008-5472.CAN-13-1506
9. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller HE, Guleria I, Barth RJ, Huang YH, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci USA 2015; 112(21):6682-7; PMID:25964334; http://dx.doi.org/10.1073/pnas.1420370112
10. Kondo Y, Ohno T, Nishii N, Harada K, Yagita H, Azuma M. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol 2016; 57:54-60; PMID:27208845; http://dx.doi.org/10.1016/j.oraloncology.2016.04.005
11. Metzger ML, Behrens HM, Böger C, Haag J, Krüger S, Röcken C. MET in gastric cancer–discarding a 10% cutoff rule. Histopathology 2015; 68(2):241-53; PMID:26033401; http://dx.doi.org/10.1111/his.12745
12. Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O'Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res 2014; 74(7):1924-32; PMID:24691993; http://dx.doi.org/10.1158/0008-5472.CAN-13-1504
13. Lines JL, Sempere LF, Broughton T, Wang L, Noelle R. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res 2014; 2(6):510-517; PMID:24894088; http://dx.doi.org/10.1158/2326-6066.CIR-14-0072
14. Oliveira P, Carvalho J, Rocha S, Azevedo M, Reis I, Camilo V, Sousa B, Valente S, Paredes J, Almeida R, et al. Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation. Sci Rep 2016; 6:34860; PMID:27721458; http://dx.doi.org/10.1038/srep34860
15. Aloia L, Parisi S, Fusco L, Pastore L, Russo T. Differentiation of embryonic stem cells 1 (Dies1) is a component of bone morphogenetic protein 4 (BMP4) signaling pathway required for proper differentiation of mouse embryonic stem cells. J Biol Chem 2010; 285(10):7776-83; PMID:20042595; http://dx.doi.org/10.1074/jbc.M109.077156
16. Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, Demirci U, Uner A, Dursun A, Atak EY, et al. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites. Jpn J Clin Oncol 2015; 45(5):416-21; PMID:25732909; http://dx.doi.org/10.1093/jjco/hyv020
17. Lauren T. The two histologic main types of gastric carcinoma:diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965; 64:31-49; PMID:14320675
18. Sobin LH, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours. Weinheim, Germany:Wiley-Blackwell; 2009.
19. Böger C, Haag J, Egberts JH, Röcken C. Complex APC germline mutation associated metaplasia and intraepithelial neoplasia (CAM-IEN) of the gallbladder. Pathol Res Pract 2015; 212(1):54-8; PMID:26643927; http://dx.doi.org/10.1016/j.prp.2015.11.010
20. Mathiak M, Warneke VS, Behrens HM, Haag J, Böger C, Krüger S, Röcken C. Clinicopathologic characteristics of microsatellite instable gastric carcinomas revisited:urgent need for standardization. Appl Immunohistochem Mol Morphol 2017; 25(1):12-24; PMID:26371427; http://dx.doi.org/10.1097/PAI.0000000000000264
21. Röcken C, Behrens HM, Böger C, Krüger S. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort. J Clin Pathol 2016; 69(1):70-5; PMID:26251521; http://dx.doi.org/10.1136/jclinpath-2015-202980
22. Warneke VS, Behrens HM, Böger C, Becker T, Lordick F, Ebert MP, Röcken C. Her2/neu testing in gastric cancer:evaluating the risk of sampling errors. Ann Oncol 2013; 24(3):725-33; PMID:23139264; http://dx.doi.org/10.1093/annonc/mds528
23. Warneke V, Behrens HM, Haag J, Balschun K, Böger C, Becker T, Ebert MPA, Lordick F, Röcken C. Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol 2013; 22(3):127-37; PMID:23846438; http://dx.doi.org/10.1097/PDM.0b013e318284188e
24. Benjamini Y. Discovering the false discovery rate. J R Stat Soc B:Stat Methodol 2010; 72:405-16; http://dx.doi.org/10.1111/j.1467-9868.2010.00746.x